BioVie Inc. (BIVI)

NASDAQ: BIVI · Real-Time Price · USD
1.350
-0.120 (-8.16%)
At close: May 11, 2026, 4:00 PM EDT
1.430
+0.080 (5.93%)
After-hours: May 11, 2026, 4:19 PM EDT
Market Cap10.18M -38.3%
Revenue (ttm)n/a
Net Income-17.48M
EPS-4.15
Shares Out 7.54M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume179,147
Open1.470
Previous Close1.470
Day's Range1.350 - 1.540
52-Week Range1.060 - 12.100
Beta0.72
Analystsn/a
Price Targetn/a
Earnings DateMay 22, 2026

About BIVI

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 13
Stock Exchange NASDAQ
Ticker Symbol BIVI
Full Company Profile

Financial Performance

Financial Statements

News

BioVie Transcript: KOL event

The event highlighted the central role of metabolic dysregulation and inflammation in Parkinson's and Alzheimer's, emphasizing bezisterim's potential to address both motor and non-motor symptoms. Key biomarkers include DNA methylation and quality of life measures, with trial results expected by end of Q2 or early Q3.

4 days ago - Transcripts

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...

14 days ago - GlobeNewsWire

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

The presentation highlighted imminent clinical data readouts for bezisterim in Parkinson's and long COVID, both representing multi-billion dollar U.S. market opportunities. The company is advancing a spin-off for its liver disease asset and is considered undervalued with strong insider ownership.

25 days ago - Transcripts

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...

27 days ago - GlobeNewsWire

BioVie Transcript: Status update

Bezisterim is advancing in phase II trials for Parkinson's and long COVID, with key data readouts expected in Q2 and late summer 2024. BIV201 for ascites is preparing for phase III after strong phase II results. Strategic focus is on Parkinson's, with long COVID as a potential priority if results and FDA guidance are favorable.

2 months ago - Transcripts

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right...

3 months ago - GlobeNewsWire

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

BioVie (BIVI) completed enrollment of 60 patients in its Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in individuals with early-st...

4 months ago - TheFly

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...

4 months ago - PRNewsWire

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodeg...

6 months ago - GlobeNewsWire

BioVie Transcript: AGM 2025

The meeting established a quorum, elected six directors for a one-year term, ratified EisnerAmper, LLP as auditor for 2026, and approved an amendment to the 2019 Omnibus Equity Incentive Plan. All proposals passed with strong majority support.

6 months ago - Transcripts

BioVie Transcript: Investor Update

Multiple clinical trials are progressing, with key data readouts for Parkinson's, Long COVID, and ascites expected by mid-2026. Lead drug bezisterim targets TNF-alpha and shows promise in neurodegenerative and inflammatory conditions, while financial runway extends through 2026.

7 months ago - Transcripts

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...

8 months ago - GlobeNewsWire

BioVie price target adjusted to $12 from $6 at Brookline

Brookline adjusted the firm’s price target on BioVie (BIVI) to $12 from $6 and keeps a Buy rating on the shares. The firm cites the company’s recent 1-for-10 reverse stock…

9 months ago - TheFly

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue ...

9 months ago - GlobeNewsWire

Why Is BioVie Stock (BIVI) Down 50% Today?

BioVie stock was down on Friday after the company priced shares in a public offering.

9 months ago - TipRanks

BioVie 6M share Secondary priced at $2.00

The deal priced below last closing price of $2.91. ThinkEquity is acting as sole book running manager for the offering.

9 months ago - TheFly

BioVie Inc. Announces Pricing of $12 Million Public Offering

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debi...

9 months ago - GlobeNewsWire

BioVie presents data on Bezisterim at WCAG-2025

BioVie (BIVI) presented “Bezisterim Decreases Biological Age Acceleration in Alzheimer’s Disease” at the 2nd World Conference on Aging and Gerentology, WCAG-2025, in Rome, Italy July 14-15, 2025. Bezi...

10 months ago - TheFly

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging Bezisterim treatment appears to be associated with changes in DNA...

10 months ago - GlobeNewsWire

BioVie appoints Amy Chappell, Kameel Farag to board of directors

BioVie (BIVI) announced the appointment of Amy Chappell, MD, FAAN, and Kameel Farag to its Board of Directors. Currently, as CMO of Solaxa Inc., Chappelloversees clinical development of novel therapie...

10 months ago - TheFly

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission Seasoned leaders bring deep expertise in neuroscience drug d...

10 months ago - GlobeNewsWire

BioVie reports results from bezisterim Phase 3 NM101 study

BioVie (BIVI) presented “Bezisterim Epigenetic Effects on Aging and Neurodegeneration” at the 7th World Aging and Rejuvenation Conference, or ARC-2025, taking place in Vienna, Austria, July 9th -10th....

10 months ago - TheFly

BioVie Inc. trading halted, news pending

16:50 EDT BioVie (BIVI) Inc. trading halted, news pending

11 months ago - TheFly

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

BioVie (BIVI) announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical trial will be presented at the Advanced Therapeutics in Movem...

11 months ago - TheFly

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes p...

11 months ago - GlobeNewsWire